NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PA-17-197 from the NIH Guide for Grants and Contracts. Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.
Funding Opportunity PA-17-198 from the NIH Guide for Grants and Contracts. Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.
Funding Opportunity PA-17-196 from the NIH Guide for Grants and Contracts. Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.
Funding Opportunity PA-17-202 from the NIH Guide for Grants and Contracts. This FOA encourages applications for research on hearing health care in adults in support of improving access and affordability. Further research is needed to strengthen the evidence base with a goal of delivering better hearing health care outcomes in adults.
Notice NOT-CA-17-034 from the NIH Guide for Grants and Contracts
Notice NOT-DK-17-009 from the NIH Guide for Grants and Contracts
Notice NOT-HD-17-001 from the NIH Guide for Grants and Contracts
Notice NOT-HG-17-001 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-040 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-039 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-491 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-490 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-038 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-17-017 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.
Funding Opportunity RFA-CA-17-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.
Funding Opportunity RFA-DA-18-002 from the NIH Guide for Grants and Contracts. This FOA supports highly innovative R01 applications on HIV/AIDS and drug abuse and complements the Avant-Garde Award Program for HIV/AIDS and Drug Use Research and the Avenir Award Program for Research on Substance Abuse and HIV/AIDS. The Avant-Garde award supports individuals who conduct high-risk, high-reward research and does not require a detailed research plan. The Avenir award is similar to the Avant-Garde award but focuses on support for early stage investigators. Applications submitted under this FOA are required to have a detailed research plan and preliminary data. This FOA focuses on innovative research projects that have the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention and treatment of HIV/AIDS among substance abusers. The nexus with drug abuse should be clearly described. This FOA is open to both individual researchers and research teams and is not limited to any one area of research on HIV and substance use, but all studies must focus on NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html.
Funding Opportunity PA-17-194 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages implementation research projects designed in partnership with global and domestic service providers, to target the particular needs in the selected community, to achieve the 90/90/90 HIV prevention and treatment targets identified by HIV/AIDS global leadership. The targets for HIV testing are that 90% of all persons living with HIV know their status, for treatment initiation that 90% of those diagnosed receive timely and effective antiretroviral treatment (ART), and for optimal treatment and preventive benefit that 90% of those on treatment achieve sustained viral suppression.
Funding Opportunity PA-17-195 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages implementation research projects designed in partnership with global and domestic service providers, to target the particular needs in the selected community, to achieve the 90/90/90 HIV prevention and treatment targets identified by HIV/AIDS global leadership. The targets for HIV testing are that 90% of all persons living with HIV know their status, for treatment initiation that 90% of those diagnosed receive timely and effective antiretroviral treatment (ART), and for optimal treatment and preventive benefit that 90% of those on treatment achieve sustained viral suppression.
Funding Opportunity PAR-17-190 from the NIH Guide for Grants and Contracts. The Maximizing Investigators' Research Award (MIRA) under this FOA is a grant to provide support for the program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program of research is the collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this mechanism will: Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively. Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies. More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs. Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research. Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment.
Funding Opportunity PAR-17-188 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.